Patent Application: Composition for Mitigating Veisalgia and Nausea

ChangeBridge: Patent Apps - Pharma (A61K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

View original document View source feed page

What changed

This document is a patent application filed with the USPTO, detailing a novel composition for mitigating veisalgia (hangover) symptoms and nausea. The proposed formulation includes dihydromyricetin, acetylcysteine, and an antiemetic selected from a group including phosphoric acid, ginger, peppermint, lemon, and bismuth subsalicylate. It also specifies preferred packaging forms (liquid, capsule, tablet, chewable) and notes the exclusion of free form taurine to avoid nausea, while suggesting neuroprotective forms like magnesium acetyl taurate.

As this is a patent application, it does not impose immediate regulatory requirements or compliance deadlines on entities. However, it signifies potential future developments in the pharmaceutical or supplement market for hangover remedies. Companies involved in drug development, particularly in the areas of gastrointestinal health or novel therapeutic compositions, should be aware of this filing as it may impact future product innovation and intellectual property landscapes.

Source document (simplified)

← USPTO Patent Applications

MITIGATION OF VEISALGIA AND NAUSEA AND METHODS THEREOF

Application US20260083695A1 Kind: A1 Mar 26, 2026

Inventors

April Hang

Abstract

An orally deliverable composition for reducing veisalgia symptoms and nausea in a subject includes dihydromyricetin, acetylcysteine, and an antiemetic that decreases smooth muscle contraction in the digestive tract. The antiemetic is selected from the group consisting of phosphoric acid, ginger, peppermint, lemon, bismuth subsalicylate, and combinations thereof in an amount sufficient to decrease smooth muscle contraction and inhibit nausea in the subject. The composition is packaged as a viscous liquid, capsule, tablet or chewable form for oral administration. The composition preferably contains no free form taurine amino acid to avoid taurine-induced nausea. The composition may contain neuroprotective forms of taurine such as magnesium acetyl taurate which is not known to cause nausea in subjects and which can pass the blood brain barrier to protect the brain from some effects of veisalgia.

CPC Classifications

A61K 31/198 A61K 31/164 A61K 31/185 A61K 31/191 A61K 31/194 A61K 31/353 A61K 31/375 A61K 31/455 A61K 31/525 A61K 31/60 A61K 31/675 A61K 31/714 A61K 33/08 A61K 33/42 A61K 36/28 A61K 36/534 A61K 36/752 A61K 36/9068